Impressive 40% response in Phase II Bisantrene AML Trial
Filed with ASX · · 8 pages · English
In the deck
Earlier from Racura Oncology
- Managing Director Resignation
- Race starts preclinical breast cancer study for Bisantrene
- Race Secures A$1.8m strategic placement
- December 2019 Quarterly Report
- Race Receives $159k R&D Tax Incentive Refund
Later from Racura Oncology
- Extension of time to repay loan through share buy-back
- A$3m strategic investment from prominent biotech investors
- Strategic investors make further $1.5m investment in Race
- Race leadership team strengthened
- Prof Borje S Andersson appointed Chief Medical Officer
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology